CN116448996A - Preparation method of polymerase-antibody complex with bead structure - Google Patents
Preparation method of polymerase-antibody complex with bead structure Download PDFInfo
- Publication number
- CN116448996A CN116448996A CN202310286211.5A CN202310286211A CN116448996A CN 116448996 A CN116448996 A CN 116448996A CN 202310286211 A CN202310286211 A CN 202310286211A CN 116448996 A CN116448996 A CN 116448996A
- Authority
- CN
- China
- Prior art keywords
- horseradish peroxidase
- antibody
- polymerase
- bead
- antibody complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011324 bead Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims abstract description 65
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 31
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims abstract description 30
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 15
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims abstract description 10
- 230000008878 coupling Effects 0.000 claims abstract description 3
- 238000010168 coupling process Methods 0.000 claims abstract description 3
- 238000005859 coupling reaction Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 32
- 238000006243 chemical reaction Methods 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 19
- 238000011033 desalting Methods 0.000 claims description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims description 16
- 229920001223 polyethylene glycol Polymers 0.000 claims description 16
- 239000007853 buffer solution Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 241000283707 Capra Species 0.000 claims description 10
- 238000006116 polymerization reaction Methods 0.000 claims description 10
- 230000000903 blocking effect Effects 0.000 claims description 7
- 150000004985 diamines Chemical class 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 6
- 102000003992 Peroxidases Human genes 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 6
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 4
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 claims description 4
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims description 4
- 239000002808 molecular sieve Substances 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 4
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 102000006783 calponin Human genes 0.000 claims description 3
- 108010086826 calponin Proteins 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 102100036912 Desmin Human genes 0.000 claims description 2
- 108010044052 Desmin Proteins 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 102000008071 Mismatch Repair Endonuclease PMS2 Human genes 0.000 claims description 2
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 2
- 241000220259 Raphanus Species 0.000 claims description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 2
- 102100027188 Thyroid peroxidase Human genes 0.000 claims description 2
- 101710113649 Thyroid peroxidase Proteins 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000005045 desmin Anatomy 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 108010084424 CK-34 beta E12 Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 12
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 238000013115 immunohistochemical detection Methods 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 3
- 239000012188 paraffin wax Substances 0.000 abstract description 3
- 229910021529 ammonia Inorganic materials 0.000 abstract 1
- 239000012467 final product Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 238000004043 dyeing Methods 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 240000003291 Armoracia rusticana Species 0.000 description 8
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 238000007789 sealing Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000002055 immunohistochemical effect Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 5
- 108010076876 Keratins Proteins 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 229920001503 Glucan Polymers 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 238000007447 staining method Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000412 dendrimer Substances 0.000 description 2
- 229920000736 dendritic polymer Polymers 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012758 nuclear staining Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- GTDOPRQDTRLYAL-UHFFFAOYSA-N hydrogen peroxide;methanol Chemical compound OC.OO GTDOPRQDTRLYAL-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a preparation method of a polymerase-antibody complex with a bead structure, which comprises the following steps of (1) using sodium periodate to aldehyde horseradish peroxidase; (2) Synthesizing the poly horseradish peroxidase with a bead structure by using a double-ammonia crosslinking reagent; (3) Introducing a hydrophilic arm chain on the horse radish peroxidase with the bead structure; (4) Coupling the antibody to the horseradish peroxidase introduced into the hydrophilic arm chain to obtain the final product. The prepared polyase-antibody complex with the bead structure has wide application in chemiluminescent in-vitro diagnostic reagents, elisa detection reagents, conventional paraffin section immunohistochemical detection reagents and intraoperative frozen section immunohistochemical detection reagents, and can greatly improve the detection sensitivity.
Description
Technical Field
The invention belongs to the technical field of medical detection, and particularly relates to a preparation method of a polymerase-antibody complex with a bead structure.
Background
Histochemistry (immunochemistry) is a technology for locating, qualitatively and relatively quantitatively detecting specific antigens in tissue cells by using the specific binding principle of antigens and antibodies and a special labeling technology, and making secondary antibodies labeled with fluorescein, enzyme, metal ions and isotopes develop color under the action of a display agent through chemical reaction. Immunohistochemical (IHC) staining has extremely important significance for judging tumors and guiding medicines, the analysis of the immunohistochemistry of the tumors in the hospital pathology department is extremely important for parting tumor molecules, and accurate tumor parting detection is beneficial to guiding patients to accurately take medicines, improves treatment effect and reduces toxic and side effects.
The development of the immunohistochemical secondary antibody technology is carried out by a direct method, an indirect method, an enzyme-labeled streptavidin-biotin staining method and an enzyme-labeled polymer staining method. Among them, the direct method and indirect method have low sensitivity due to weak signal amplification efficiency, and are rarely applied at present; in the enzyme-labeled streptavidin-biotin staining method, the ABC complex can be combined with biotin commonly existing in cell tissues, so that severe nonspecific staining is generated, interpretation of results is greatly interfered, and therefore, the method is phased out in clinical immunoassay at present; enzyme-labeled multimeric staining is the mainstream technology in clinical application at present, and the method is to label enzymes on a main chain taking inert glucan, polylysine, polypeptide, dendrimer and the like as a framework to form multimeric enzymes, and then connect antibodies to the multimeric enzymes to obtain multimeric enzyme-antibody complexes. Each main chain can be connected with 4-70 enzyme molecules and 1-10 antibody molecules, so that the method has extremely strong signal amplification effect, and simultaneously, the non-biotin detection system is used, so that non-specific staining caused by endogenous biotin is avoided, and the method is widely applied clinically. However, this method is not perfect, and its main technical drawbacks are: the method adopts a glucan polymer skeleton with the molecular weight of more than or equal to 50 ten thousand, and is connected with 4-70 enzyme molecules and 1-10 antibody molecules, so that the structure is loose, the hydrodynamic volume is huge, and the great steric hindrance is caused, so that the penetration of the polymer to a cell nuclear membrane is low. Thus, the polymer exhibits poor performance in the detection of various different types of antigens, especially in the detection of low-expression antigens in some nuclei.
In addition, since most secondary antibodies are prepared by serially connecting a large amount of horseradish peroxidase and antibodies by adopting an amino-bearing skeleton, the molecular weight of the obtained secondary antibodies is basically more than 1000kd, and the large secondary antibody molecules have strong charges and strong hydrophobicity and are easy to generate nonspecific binding with tissue sections through static electricity and hydrophobic interaction, so that nonspecific background staining is caused, and the secondary antibodies are a great difficulty which is most difficult to solve in the development of the secondary antibodies.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention provides a preparation method of a polymerase-antibody complex with a bead structure, which does not adopt a skeleton to prepare the polymerase, adopts small-molecule diammine polyethylene glycol as a cross-linking agent to synthesize the polymerase with the bead structure, so that the polymerase molecule is as compact as possible, the space occupation is smaller, and the prepared polymerase-antibody complex has better tissue penetration capability and higher detection sensitivity to smaller tissue cell structures when being used for tissue section staining; meanwhile, as a framework is not adopted and a small-molecule hydrophilic cross-linking agent is adopted, the chargeability of the secondary antibody is reduced, the hydrophilicity of the secondary antibody is improved, the electrostatic and hydrophobic combination between the secondary antibody and a tissue slice is greatly weakened, and the background dyeing caused by the nonspecific effect between the secondary antibody and the tissue slice is effectively reduced.
The invention adopts the technical scheme that:
a method for preparing a polymerase-antibody complex of a bead structure, comprising the steps of:
step one: horseradish peroxidase was aldehyde-formed using sodium periodate:
a. weighing a certain amount of horseradish peroxidase, and dissolving the horseradish peroxidase in the buffer solution A to obtain a horseradish peroxidase solution with a certain concentration;
b. weighing a certain amount of sodium periodate to be dissolved in purified water;
c. adding a sodium periodate aqueous solution into a horseradish peroxidase solution, and reacting for 5-60 minutes at 15-40 ℃;
d. finishing the reaction, and passing through a desalting column to obtain aldehyde activated horseradish peroxidase;
step two: synthesis of bead structured multimeric horseradish peroxidase using a diamine cross-linking reagent:
e. preparing aldehyde-activated horseradish peroxidase into a certain concentration;
f. adding a diamine crosslinking reagent, and adjusting the pH of a reaction system to be 7.5-10.0,20-30 ℃ for reaction for 1-16 hours;
g. adding a reducing agent, and reacting for 1-4 hours;
h. adding a blocking reagent, and reacting for 2-6 hours;
i. finishing the reaction, and passing through a desalting column to obtain the poly horseradish peroxidase with a bead structure;
step three: introducing a hydrophilic arm chain on the horse radish peroxidase with a bead structure:
j. preparing the polymeric horseradish peroxidase with a bead structure into a concentration of 1-20 mg/mL;
k. dissolving a hydrophilic arm chain reagent in a proper buffer solution to prepare 5-20 mg/mL;
mixing hydrophilic arm chain reagent and horse radish peroxidase in the molar ratio of 10 to 1-80 to 1, and reacting at room temperature for 0.5-4 hr;
finishing the reaction, and passing through a desalting column to obtain the poly-horseradish peroxidase containing the hydrophilic arm chain;
step four: coupling the antibody to the polyhorse radish peroxidase with a hydrophilic arm chain to finally obtain the polyenzyme-antibody complex with a bead structure:
dissolving the antibody in a proper solution to prepare 1-10 mg/mL;
dissolving sulfhydrylation reagent in proper solution to prepare 0.5-10 mg/mL;
p, mixing the sulfhydrylation reagent and the antibody together according to the mol ratio of 1:1-20:1, and reacting for 0.5-3 hours at room temperature;
finishing the reaction, and passing through a desalting column to obtain the sulfhydryl modified antibody;
and r, the mole ratio of the poly horseradish peroxidase to the sulfhydryl modified antibody is 8-20: 1, mixing the two materials together, and reacting for 12-72 hours at the temperature of 2-8 ℃;
and s, passing through a molecular sieve purification column, and collecting target peaks to obtain the polymerase-antibody complex with the bead structure.
In the first step, the buffer solution A is a citric acid buffer solution, the pH value is 4.0-7.0, and the preferable pH value is 5.0;
in the first step, the concentration of the sodium periodate aqueous solution is 5-50 mg/mL, preferably 20-30 mg/mL, and the concentration of the horseradish peroxidase solution is 1-50 mg/mL, preferably 20-40 mg/mL.
In the first step, the molar ratio of the sodium periodate to the horseradish peroxidase is 10-400, and the preferable molar ratio is 40-100; the reaction temperature in the first step is 15-40 ℃ and the reaction time is 5-60 minutes;
the desalting column in the first step is a PD-10 desalting column.
In the second step, the chemical structure of the diamine cross-linking reagent is shown in the following formula 1,
the diamine cross-linking agent of formula 1 has a chemical structure wherein n represents the degree of polymerization of polyethylene glycol (PEG) and ranges from 2 to 100, preferably from 10 to 50.
In the second step, the concentration of aldehyde-activated horseradish peroxidase is 1-40 mg/mL, preferably 10-30 mg/mL. In the step f, the pH of the reaction system is 8-10.5, preferably 9-10, the reaction temperature is 15-40 ℃, preferably 25-35 ℃ and the reaction time is 4 hours
In the second step, the reducing agent is sodium borohydride.
The blocking reagent in the second step comprises any one of ethylenediamine, 1, 3-propylenediamine, 3' -diaminodipropylamine, lysine and diammine polyethylene glycol with the polymerization degree of 2-5 shown in the formula 1.
In the second step, the serial number of the horseradish peroxidase in the polymer horseradish peroxidase with the bead structure is 6-32, preferably 10-20.
In the third step, the chemical structure of the hydrophilic arm chain reagent is shown in the following formula 2,
the chemical structural formula of the hydrophilic arm chain reagent of formula 2, wherein n represents the polymerization degree of polyethylene glycol (PEG), is in the range of 6 to 50, preferably in the range of 10 to 30.
The concentration of the polymeric horseradish peroxidase with the bead structure in the third step is 1-40 mg/mL, preferably 10-20 mg/mL; the concentration of the hydrophilic arm chain reagent is 10-50 mg/mL, preferably 20-40 mg/mL, the buffer solution is 10mM PBS buffer solution, and the pH is 5.0-8.0, preferably 7.0-8.0
The molar ratio of the horseradish peroxidase polymer to the hydrophilic arm chain reagent is 1:10-1:60, preferably 1:15-1:30.
The reaction time is 1.5 hours, and the reaction temperature is 15-25 ℃.
In the fourth step, the concentration of the antibody is 1-10 mg/mL, the concentration of the solution for dissolving the antibody is 10mM PBS,10mM EDTA,pH8.0, the concentration of the sulfhydrylation reagent is 1mg/mL, the proper solution is 10mM PBS,10mM EDTA,pH8.0, and the molar ratio of the horseradish peroxidase to the antibody in the obtained polymerase-antibody complex with the bead structure is 6:1-20:1, preferably 6:1-12:1.
In step four, the antibodies referred to include monoclonal antibodies, polyclonal antibodies, fab fragments, fab'2 fragments, wherein monoclonal antibodies include, but are not limited to, (CK PAN, CK19, MUC1 CK5/6, p63, calponin CK19, TPO, CD56 MUC-1TPO MC CK34. Beta.E12 Galectin-3CT CEA SYN CgA TTF-1Napsin A Ki-67 PMS2 P16 CD34 S100 DESMIN P53); polyclonal antibodies include, but are not limited to, goat anti-rabbit and goat anti-mouse; fab fragments and Fab '2 fragments include, but are not limited to, fab fragments and Fab'2 fragments of the monoclonal and polyclonal antibodies listed above.
The serial number of the polymerase-antibody complex with the bead structure prepared by the method is 6-32, the structural characteristics are shown in the following formula 3, and the HRP is firstly connected in series to form the multimeric HRP enzyme by taking small-molecule diammine polyethylene glycol as a cross-linking agent; then connecting the antibody or antibody fragment to the polymeric HRP through a hydrophilic cross-linking agent with a long arm chain, so that the polymeric enzyme molecule is as compact as possible, the space occupation is smaller, and the prepared polymeric enzyme-antibody compound has better tissue penetration capability when being used for tissue section dyeing and higher detection sensitivity to smaller tissue cell structures; meanwhile, as a framework is not adopted and a small-molecule hydrophilic cross-linking agent is adopted, the chargeability of the secondary antibody is reduced, the hydrophilicity of the secondary antibody is improved, the electrostatic and hydrophobic combination between the secondary antibody and a tissue slice is greatly weakened, and the background dyeing caused by the nonspecific effect between the secondary antibody and the tissue slice is effectively reduced.
The polyase-antibody complex with the bead structure has very wide application in the aspects of intraoperative frozen section immunohistochemistry, conventional paraffin section immunohistochemistry, chemiluminescence in-vitro diagnosis and the like.
The structure of the polymerase-antibody complex with the bead structure is shown in the formula 3, wherein circles represent horseradish peroxidase and Y represents an antibody.
The polyase-antibody complex with the bead structure has wide application in chemiluminescent in-vitro diagnostic reagents, elisa detection reagents, conventional paraffin section immunohistochemical detection reagents and intraoperative frozen section immunohistochemical detection reagents, and can greatly improve the detection sensitivity.
The beneficial effects are that:
compared with the related art, the preparation and application of the polymerase-antibody complex with the bead structure provided by the invention have the following advantages:
(1) The macromolecular glucans, dendritic polymers and other skeletons are not adopted, and small-molecule diammine polyethylene glycol is adopted as a cross-linking agent to synthesize the polymerase with a bead structure, so that the polymerase molecules are as compact as possible, and the space occupation is smaller;
(2) Meanwhile, hydrophilic diammine polyethylene glycol is used as a cross-linking agent, so that the cross-linking effect is achieved, the hydrophilic modification effect on the polymerase is achieved, the prepared polymerase is better in water solubility, and the aggregation of the polymerase and the dyeing background caused by the hydrophobic effect during tissue slice dyeing are reduced;
(3) A long hydrophilic arm chain is introduced into the polymerase, so that the antibody connected to the polymerase has higher flexibility, and is favorable for free combination of the antibody and antigen; meanwhile, the hydrophilic arm chain is introduced to greatly improve the hydrophilicity of the polymerase-antibody complex, and reduce the aggregation of the polymerase-antibody complex and the dyeing background caused by the hydrophobic effect during tissue section dyeing;
the 3 points are combined, so that the polymerase-antibody complex has better tissue penetration capability when being used for tissue section staining, has higher detection sensitivity on smaller tissue cell structures, and can effectively reduce the staining background.
Drawings
FIG. 1AR shows the secondary antibody prepared in example 5 to the left of the imported secondary antibody and to the right of the imported secondary antibody, with the advantage that the nuclear staining intensity is superior to the imported secondary antibody;
FIG. 2BerEP4 lung adenocarcinoma is followed by the imported secondary antibody and the secondary antibody prepared by the method of example 5, with the advantage that the cytoplasmic color intensity is superior to the imported secondary antibody;
FIG. 3 shows the right side of the CD10 lymph node with the imported secondary antibody and the right side with the secondary antibody prepared by the method of example 6, wherein the cell membrane staining intensity is superior to that of the imported secondary antibody;
FIG. 4KI67 shows the secondary antibody on the left of the tonsil and the secondary antibody on the right of the secondary antibody prepared by the method of example 6, with the advantage that the nuclear staining intensity is superior to that of the secondary antibody;
FIG. 5CK5/6 shows the secondary antibody of the intra-operative frozen section prepared by the method of example 2 on the left and the commercial quick freezing reagent on the right, and the staining intensity is superior to that of the secondary antibody of the commercial intra-operative frozen section.
Detailed Description
EXAMPLE 1 preparation of multimeric horseradish peroxidase-CK 5/6 antibody Complex with 16-24 peroxidase tandem
a. 300mg of horseradish peroxidase is weighed and dissolved in 100mL of citric acid buffer solution with pH of 6.0, so as to obtain 10mg/mL of horseradish peroxidase solution;
b. 80mg of sodium periodate is weighed and dissolved in purified water to obtain a sodium periodate aqueous solution with the concentration of 20mg/mL;
c. adding a sodium periodate aqueous solution into a horseradish peroxidase solution, and reacting for 15 minutes at 37 ℃;
d. finishing the reaction, and passing through a PD-10 desalting column to obtain aldehyde activated horseradish peroxidase;
e. preparing aldehyde-activated horseradish peroxidase into 20mg/mL;
f. adding 10mg of diamino polyethylene glycol with the polymerization degree of 24, adjusting the pH value of a reaction system to 10.0, and reacting for 4 hours at room temperature;
g. 5mg of sodium borohydride is added and the mixture is reacted for 2 hours at room temperature;
adding 0.5g of blocking reagent ethylenediamine, and reacting for 2 hours at room temperature;
i. finishing the reaction, and passing through a desalting column to obtain the poly horseradish peroxidase with a bead structure;
j. preparing the polymeric horseradish peroxidase with a bead structure into 15mg/mL;
k. dissolving a hydrophilic arm chain reagent with the polymerization degree of 8 in 10mM PBS buffer solution, and preparing 20mg/mL;
mixing the two materials together, and reacting for 1.5 hours at room temperature;
finishing the reaction, and passing through a PD-10 desalting column to obtain the horseradish peroxidase polymer containing hydrophilic arm chains; dissolving cytokeratin CK5/6 antibody in 10mM PBS,10mM EDTA,pH8.0 to prepare 6mg/mL; dissolving a sulfhydrylation reagent in 10mM PBS,10mM EDTA,pH8.0 solution to prepare 1mg/mL; p, mixing the two materials together, and reacting for 1 hour at room temperature;
finishing the reaction, and passing through a desalting column to obtain the sulfhydryl modified antibody;
mixing the thiol-modified cytokeratin CK5/6 antibody with the horseradish peroxidase with a hydrophilic arm chain according to the mol ratio of 1:30, and reacting for 24 hours at the temperature of 2-8 ℃;
s, passing through a molecular sieve purification column, and collecting a first out target peak to obtain the poly horseradish peroxidase-CK 5/6 antibody complex with a bead structure.
EXAMPLE 2 preparation of multimeric horseradish peroxidase-Ki-67 antibody Complex with 16-24 horseradish peroxidase tandem numbers
The procedure is as in example 1, except that the cytokeratin CK5/6 antibody is replaced with Ki-67.
(FIG. 5)
Example 3 preparation of a multimeric horseradish peroxidase-P63 antibody complex with 16-24 horseradish peroxidase tandem numbers.
The procedure is as in example 1, except that the cytokeratin CK5/6 antibody is replaced with P63.
EXAMPLE 4 preparation of multimeric horseradish peroxidase-Calponin antibody Complex with 16-24 horseradish peroxidase tandem numbers
The procedure is as in example 1, except that the cytokeratin CK5/6 antibody is replaced with Calponin. Example 5 preparation of multimeric horseradish peroxidase-goat anti-rabbit polyclonal antibody complex with number of horseradish peroxidase tandem of 8-12
a. 300mg of horseradish peroxidase is weighed and dissolved in 100mL of citric acid buffer solution with pH of 6.0, so as to obtain 10mg/mL of horseradish peroxidase solution;
b. 80mg of sodium periodate is weighed and dissolved in purified water to obtain 20mg/mL solution;
c. adding a sodium periodate aqueous solution into a horseradish peroxidase solution, and reacting for 10 minutes at 37 ℃;
d. and (3) finishing the reaction, and passing through a desalting column to obtain the aldehyde-activated horseradish peroxidase.
e. Preparing aldehyde-activated horseradish peroxidase into 20mg/mL;
f. adding 10mg of diamino polyethylene glycol with the polymerization degree of 24, adjusting the pH value of a reaction system to 10.0, and reacting for 4 hours at room temperature;
g. 5mg of sodium borohydride is added and the mixture is reacted for 2 hours at room temperature;
h. adding 0.5g of blocking reagent ethylenediamine, and reacting for 2 hours at room temperature;
i. finishing the reaction, and passing through a desalting column to obtain the poly horseradish peroxidase with a bead structure;
j. preparing the polymeric horseradish peroxidase with a bead structure into 15mg/mL;
k. dissolving a hydrophilic arm chain reagent with the polymerization degree of 8 in 10mM PBS buffer solution, and preparing 20mg/mL;
mixing the two materials together, and reacting for 1.5 hours at room temperature;
finishing the reaction, and passing through a PD-10 desalting column to obtain the horseradish peroxidase polymer containing hydrophilic arm chains;
dissolving goat anti-rabbit polyclonal antibody in 10mM PBS,10mM EDTA,pH8.0 to prepare 6mg/mL;
dissolving a sulfhydrylation reagent in 10mM PBS,10mM EDTA,pH8.0 solution to prepare 1mg/mL;
p, mixing the two materials together, and reacting for 1 hour at room temperature;
finishing the reaction, and passing through a PD-10 desalting column to obtain a sulfhydryl modified antibody;
mixing the thiol-modified goat anti-rabbit polyclonal antibody with the poly horseradish peroxidase with the hydrophilic arm chain according to the mol ratio of 1:20, and reacting for 24 hours at the temperature of 2-8 ℃;
s, passing through a molecular sieve purification column, and collecting a first separation peak to obtain the poly horseradish peroxidase-goat anti-rabbit polyclonal antibody complex with a bead structure. (FIG. 1 and FIG. 2)
Example 6 preparation of multimeric horseradish peroxidase-goat anti-mouse polyclonal antibody Complex with number of horseradish peroxidase tandem of 8-12
The procedure was as in example 5, except that goat anti-rabbit polyclonal antibody was replaced with goat anti-mouse polyclonal antibody (fig. 3, fig. 4).
Application example
Conventional immunohistochemical on-machine flow dewaxing: dewaxing liquid 3min x 2 dewaxing liquid 1min alcohol rinse 3 times TBS rinse 3 times;
repairing: repairing liquid 3 times repairing liquid 10min x 2 repairing liquid 18min TBS washes 4 times;
dyeing: blocking agent 8min TBS rinse 3 primary antibody 18min TBS rinse 3 primary antibody enhancement 10min TBS rinse 3 secondary antibody 20min TBS rinse 3 pure water rinse 3 DAB5min pure water rinse 5 hematoxylin 5min pure water rinse 2 TBS rinse two pure water rinse one pass;
sealing piece: sealing with xylene and gradient alcohol resin;
conventional immunohistochemical Manual flow
Dewaxing: xylene 5min 3;
antigen retrieval: EDTA9.0, cold water in 2200W, air valve air injection time 3min;
peroxidase blocking: 3% hydrogen peroxide methanol solution and ovalbumin for 8min;
an antibody selection: 32 DEG for 60min;
resistance enhancement: the method is free;
secondary antibody selection: HRP-labeled goat anti-mouse or goat anti-rabbit secondary antibody for 20min;
DAB：1:19 5min；
DAB enhancement: the method is free;
hematoxylin: 30 DEG for 5min;
returning blue: TBS for 1min;
sealing piece: sealing with xylene and gradient alcohol resin;
conventional immunohistochemical demonstration panels compare: the secondary antibody VS was imported and self-developed to immunize the secondary antibodies.
Quick freezing process
Quick freezing and dyeing: enzyme-labeled primary antibody 5min TBS washing 3 times mixing DAB5min pure water washing 4 times hematoxylin 2min pure water washing 2 times TBS washing 2 times pure water washing 1 time
Sealing piece: sealing with xylene and gradient alcohol resin;
quick freezing manual flow
Quick freezing and dyeing: enzyme-labeled primary antibody for 5min DAB:1:1:5min hematoxylin 3min blue-returning TBS1min sealing piece: sealing with xylene and gradient alcohol resin.
Claims (10)
1. A method for preparing a polymerase-antibody complex of bead structure, comprising the steps of:
step one: horseradish peroxidase was aldehyde-formed using sodium periodate:
a. weighing a certain amount of horseradish peroxidase, and dissolving the horseradish peroxidase in the buffer solution A to obtain a horseradish peroxidase solution with a certain concentration;
b. weighing a certain amount of sodium periodate to be dissolved in purified water;
c. adding a sodium periodate aqueous solution into a horseradish peroxidase solution, and reacting for 5-60 min at 15-40 ℃;
d. finishing the reaction, and passing through a desalting column to obtain aldehyde activated horseradish peroxidase;
step two: synthesis of bead structured multimeric horseradish peroxidase using a diamine cross-linking reagent:
e. preparing aldehyde-activated horseradish peroxidase into a certain concentration;
f. adding a diamine crosslinking reagent, adjusting the pH value and the reaction temperature of a reaction system, and reacting for a plurality of times;
g. adding a reducing agent, and reacting for a plurality of times;
h. adding a blocking reagent, and reacting for a plurality of times;
i. finishing the reaction, and passing through a desalting column to obtain the poly horseradish peroxidase with a bead structure;
step three: introducing a hydrophilic arm chain on the horse radish peroxidase with a bead structure:
j. preparing the poly horseradish peroxidase with a bead structure into a certain concentration;
k. dissolving a hydrophilic arm chain reagent in a proper buffer solution to prepare a certain concentration;
mixing the two materials together, and reacting for a plurality of times at room temperature;
finishing the reaction, and passing through a desalting column to obtain the poly-horseradish peroxidase containing the hydrophilic arm chain;
step four: coupling the antibody to the polyhorse radish peroxidase with a hydrophilic arm chain to finally obtain the polyenzyme-antibody complex with a bead structure:
dissolving the antibody in a proper solution to prepare a certain concentration;
dissolving sulfhydrylation reagent in proper solution to prepare a certain concentration;
p, mixing the two materials together, and reacting for a plurality of times at room temperature;
finishing the reaction, and passing through a desalting column to obtain the sulfhydryl modified antibody;
mixing the sulfhydryl modified antibody with the poly horseradish peroxidase with the hydrophilic arm chain, and reacting for a plurality of times;
and s, passing through a molecular sieve purification column, and collecting target peaks to obtain the polymerase-antibody complex with the bead structure.
2. The method of claim 1, wherein in the first step, the buffer solution a is a citric acid buffer solution with a pH of 4.0 to 7.0, preferably a pH of 5.0.
3. The method for preparing a bead structured polymerase-antibody complex according to claim 1, wherein in the first step, the molar ratio of sodium periodate to horseradish peroxidase is 10-400, preferably 40-100.
4. The method for preparing a bead structured polymerase-antibody complex according to claim 1, wherein in the second step, the chemical structure of the diamine cross-linking agent is represented by the following formula 1,
wherein n represents the degree of polymerization of polyethylene glycol (PEG) and ranges from 2 to 100, preferably from 10 to 50.
5. The method for producing a bead structured polymerase-antibody complex of claim 1, wherein in the second step, the blocking reagent comprises at least one of ethylenediamine, 1, 3-propylenediamine, 3' -diaminodipropylamine, lysine and diammine polyethylene glycol having a polymerization degree of 2 to 5.
6. The method for preparing a bead structured polymerase-antibody complex according to claim 1, wherein in the step two, the number of tandem horseradish peroxidase is 6-32, preferably 10-20, in the obtained bead structured polymerase.
7. The method for preparing a bead structured polymerase-antibody complex according to claim 1, wherein in the third step, the chemical structure of the hydrophilic arm chain reagent is represented by the following formula 2,
wherein n represents the degree of polymerization of polyethylene glycol (PEG) and ranges from 6 to 50, preferably from 10 to 30.
8. The method for preparing a bead structured polymerase-antibody complex according to claim 1, wherein in the step four, the molar ratio of horseradish peroxidase to antibody is 6:1-20:1, preferably 6:1-12:1.
9. The method of claim 1, wherein in the fourth step, the antibodies include monoclonal antibodies, polyclonal antibodies, fab fragments, fab'2 fragments, wherein the monoclonal antibodies include but are not limited to CK PAN, CK19, MUC1 CK5/6, p63, calponin CK19, TPO, CD56 MUC-1TPO MC CK34 βe12 Galectin-3CT CEASYN CgATTF-1Napsin AKi-67 PMS2 P16 CD34 S100 DESMIN P53; polyclonal antibodies include, but are not limited to, goat anti-rabbit and goat anti-mouse; fab fragments and Fab '2 fragments include, but are not limited to, fab fragments and Fab'2 fragments of the monoclonal and polyclonal antibodies listed above.
10. A bead structured polymerase-antibody complex prepared by the method of any one of claims 1 to 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310286211.5A CN116448996B (en) | 2023-03-22 | 2023-03-22 | Preparation method of polymerase-antibody complex with bead structure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310286211.5A CN116448996B (en) | 2023-03-22 | 2023-03-22 | Preparation method of polymerase-antibody complex with bead structure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116448996A true CN116448996A (en) | 2023-07-18 |
| CN116448996B CN116448996B (en) | 2023-11-21 |
Family
ID=87124707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310286211.5A Active CN116448996B (en) | 2023-03-22 | 2023-03-22 | Preparation method of polymerase-antibody complex with bead structure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116448996B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6252053B1 (en) * | 1998-09-16 | 2001-06-26 | Nichirei Corporation | Enzyme-antibody complex and a method for manufacturing the same |
| CN101080246A (en) * | 2004-04-28 | 2007-11-28 | 安希奥设备国际有限责任公司 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
| CN101262889A (en) * | 2005-09-12 | 2008-09-10 | 弗雷泽纽斯卡比德国有限公司 | Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine |
| WO2013012924A2 (en) * | 2011-07-18 | 2013-01-24 | President And Fellows Of Harvard College | Engineered microbe-targeting molecules and uses thereof |
| CN109476764A (en) * | 2016-05-16 | 2019-03-15 | 哈佛大学校长及研究员协会 | It is coupled at through CO2Aqueous biological molecule on plasma-activated surface |
| CN111551709A (en) * | 2020-05-13 | 2020-08-18 | 河南赛诺特生物技术有限公司 | Enzyme-labeled secondary antibody compound and preparation method thereof |
-
2023
- 2023-03-22 CN CN202310286211.5A patent/CN116448996B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6252053B1 (en) * | 1998-09-16 | 2001-06-26 | Nichirei Corporation | Enzyme-antibody complex and a method for manufacturing the same |
| CN101080246A (en) * | 2004-04-28 | 2007-11-28 | 安希奥设备国际有限责任公司 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
| CN101262889A (en) * | 2005-09-12 | 2008-09-10 | 弗雷泽纽斯卡比德国有限公司 | Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine |
| CN102492047A (en) * | 2005-09-12 | 2012-06-13 | 弗雷泽纽斯卡比德国有限公司 | Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine |
| WO2013012924A2 (en) * | 2011-07-18 | 2013-01-24 | President And Fellows Of Harvard College | Engineered microbe-targeting molecules and uses thereof |
| CN109476764A (en) * | 2016-05-16 | 2019-03-15 | 哈佛大学校长及研究员协会 | It is coupled at through CO2Aqueous biological molecule on plasma-activated surface |
| CN111551709A (en) * | 2020-05-13 | 2020-08-18 | 河南赛诺特生物技术有限公司 | Enzyme-labeled secondary antibody compound and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116448996B (en) | 2023-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5586368B2 (en) | N1, N12-diacetylspermine as a tumor marker | |
| JPH06509167A (en) | Water-soluble polymer-based reagents and conjugates comprising components derived from divinyl sulfone | |
| JP3781934B2 (en) | Enzyme-protein complex | |
| EP1780545B1 (en) | Probe complex | |
| JP2000088850A (en) | Enzyme antibody complex and preparation thereof | |
| WO2011129357A1 (en) | Complex of labeled probe and water-soluble carrier | |
| US8404494B2 (en) | Non-specific adsorption inhibitor, probe-bonded particles, and method for producing the same | |
| CN110383067B (en) | Anti-human hemoglobin monoclonal antibody or antibody kit, antibody immobilized insoluble carrier particles and application thereof | |
| CN112305222A (en) | Small polymer enzyme-antibody fragment, preparation and application thereof | |
| CN116448996B (en) | Preparation method of polymerase-antibody complex with bead structure | |
| US8007998B2 (en) | Polymerized conjugates for biological applications | |
| EP0974841A2 (en) | Suppression of interference in immunoassays using substances derived from the framework regions of antibodies | |
| JPH07322888A (en) | Method for testing daf molecule in feces | |
| CN113391059B (en) | Micropolymer-HRP-nano antibody compound and preparation method thereof | |
| JP4083855B2 (en) | Lung cancer prognosis test method | |
| US11366108B2 (en) | Method of producing probe-bound carrier, probe-bound carrier and method of detecting or separating target substance | |
| US9046521B2 (en) | Cancer evaluation method using haptoglobin β chain defined by antibody RM2 | |
| CN115716874B (en) | Monoclonal antibody aiming at AFP-L3 and lectin complex, kit and application thereof | |
| JP2020530852A (en) | Antibody conjugation method | |
| JP3779798B2 (en) | Measuring method of CA125 | |
| CN115032399A (en) | Rapid immunohistochemical kit and use method thereof | |
| JP2023127452A (en) | Anti-peg antibody binding material and method for detecting anti-peg antibody | |
| JPH0792456B2 (en) | Enzymatically labeled catecholamine acid metabolite | |
| CN115975024A (en) | Fucosan polyclonal antibody and application thereof in detecting fucosan | |
| CN113777298A (en) | Latex enhanced immunosuppression method kit for rapidly detecting glycocholic acid, preparation method and detection method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |